Monograph Details
|
|
Dermatological Disorders
> Psoriasis
|
|
RAPTIVA |
| Manufacturer |
|
Genentech, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Immunosuppressant. |
| Generic Name |
|
Efalizumab 125mg/vial (based on 125mg/1.25mL delivered); pwd for SC inj after reconstitution; preservative-free. |
| Indications |
|
Moderate to severe chronic plaque psoriasis in adults who are candidates for systemic or phototherapy. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Inject SC into thigh, abdomen, buttocks, or upper arm; rotate inj sites. ≥18yrs: Initially 0.7mg/kg once (conditioning dose to minimize first-dose reaction), then 1mg/kg (max 200mg) once weekly. |
| Contraindications |
|
Clinically important infections. Malignancy. |
| Precautions |
|
Chronic or history of recurrent infections. Monitor closely if new infection develops during or after treatment; discontinue if serious infection develops. History or risk of malignancy; discontinue if malignancy develops. Monitor platelets; discontinue if thrombocytopenia occurs. Monitor for flare-ups during and after therapy. Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Do not give with other immunosuppressants or live vaccines. |
| Adverse Reactions |
|
Inj site reactions, esp. with first two doses (eg, headache, chills, fever, nausea, myalgia); flu-like syndrome, acne, antibody formation, infections (may be serious), malignancies, thrombocytopenia, hemolytic anemia (discontinue if occurs), arthritis, lymphocytosis, leukocytosis, elevated transaminases. |
| Extra Text |
|
Note: Register pregnant patients exposed to efalizumab by calling (877) 727-8482. Report adverse events by calling (888) 835-2555. |
| How Supplied |
|
Single-use vials—4 (w. diluent, supplies) |
|
|
|
|
